stockrowBioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
Follow BNTX
Alert me
BioNTech SE Sponsored ADR (BNTX) EV/FCF
As of 5 November 2026, BioNTech SE Sponsored ADR (BNTX) trades at a EV/FCF of −9.6×. Over the past ten years it has ranged from −241× (February 2021) to 69.5× (December 2021); the current reading is higher than 30% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −19.9× | — |
| FY2024 | −36.1× | — |
| FY2023 | 1.9× | 19.59% |
| FY2022 | 1.5× | (97.77%) |
| FY2021 | 69.5× | — |
| FY2020 | −161× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −15.4× | — |
| Jun 2026 | 13.5× | 32.68% |
| Mar 2026 | 10.2× | — |
| Dec 2025 | −19.9× | — |
| 24 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| BBIO BridgeBio Pharma, Inc. compare | −39.7× |
| INSM Insmed, Inc. compare | −37.2× |
| ROIV Roivant Sciences Ltd. compare | −28.1× |
| BNTX BioNTech SE Sponsored ADR | −9.6× |
| GMAB Genmab A/S Sponsored ADR compare | −5.7× |
| EXEL Exelixis, Inc. compare | 14.1× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 22.9× |
| INCY Incyte Corporation compare | 29.7× |
| ASND Ascendis Pharma A/S compare | 41.1× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on BNTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement